Topological geon black holes in Einstein-Yang-Mills theory

We construct topological geon quotients of two families of Einstein-Yang-Mills black holes. For Kuenzle's static, spherically symmetric SU(n) black holes with n>2, a geon quotient exists but generically requires promoting charge conjugation into a gauge symmetry. For Kleihaus and Kunz's static, axially symmetric SU(2) black holes a geon quotient exists without gauging charge conjugation, and the parity of the gauge field winding number determines whether the geon gauge bundle is trivial. The geon's gauge bundle structure is expected to have an imprint in the Hawking-Unruh effect for quantum fields that couple to the background gauge field.Comment: 27 pages. v3: Presentation expanded. Minor corrections and addition

The Extended Coupled Cluster Treatment of Correlations in Quantum Magnets

The spin-half XXZ model on the linear chain and the square lattice are examined with the extended coupled cluster method (ECCM) of quantum many-body theory. We are able to describe both the Ising-Heisenberg phase and the XY-Heisenberg phase, starting from known wave functions in the Ising limit and at the phase transition point between the XY-Heisenberg and ferromagnetic phases, respectively, and by systematically incorporating correlations on top of them. The ECCM yields good numerical results via a diagrammatic approach, which makes the numerical implementation of higher-order truncation schemes feasible. In particular, the best non-extrapolated coupled cluster result for the sublattice magnetization is obtained, which indicates the employment of an improved wave function. Furthermore, the ECCM finds the expected qualitatively different behaviours of the linear chain and the square lattice cases.Comment: 22 pages, 3 tables, and 15 figure

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2,3,4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease

Extensions of the informative vector machine

Abstract The informative vector machine (IVM) is a practical method for Gaussian process regression and classification. The IVM produces a sparse approximation to a Gaussian process by combining assumed density filtering with a heuristic for choosing points based on minimizing posterior entropy. This paper extends IVM in several ways. First, we propose a novel noise model that allows the IVM to be applied to a mixture of labeled and unlabeled data. Second, we use IVM on a blockdiagonal covariance matrix, for “learning to learn ” from related tasks. Third, we modify the IVM to incorporate prior knowledge from known invariances. All of these extensions are tested on artificial and real data.